Lead-guided prodrug development of small molecules as GLP-1R agonists.

Bioorganic chemistry

Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.

Obstetrics and gynecology

Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.

Military medicine

Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.

The Journal of international medical research

Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.

Frontiers in endocrinology

Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report.

Case reports in gastroenterology

Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.

Journal of obesity & metabolic syndrome

Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.

Journal of translational medicine

Three things reshaping the peptide industry right now: • Medicare now covers GLP-1s for weight loss $50/mo, first time ever (launched July 1) • FDA panel decides July 23 on BPC-157, TB-500, Semax + 4 more • Novartis bet up to $1.7B on peptide drugs Federal access.

Top compounds on PeptideBase by provider coverage: 1. Semaglutide — 676 2. Tirzepatide — 444 3. BPC-157 — 402 4. NAD+ — 349 5. Sermorelin — 333 6. Ipamorelin — 320 7. CJC-1295 — 306 Coverage = where the market concentrated, not where the evidence is. Disclaimer: Research use

Who the July 23–24 peptide panel is made up of might be the biggest tell we have that the peptide bull market is just getting started. Reuters reported that 7 of the 14 panelists have ties to peptide clinics or peptide therapy businesses. If that’s not a sign that a handful of

We just crossed 2,000 Reptides subscribers, and we're climbing fast. Reptides Briefs is core to what we're building. It's our editorial platform: a free monthly newsletter, plus a paid layer of deeper dives for premium members. We publish full dossiers on single peptides like

We just crossed 2,000 Reptides subscribers, and we're climbing fast. Reptides Briefs is core to what we're building. It's our editorial platform: a free monthly newsletter, plus a paid layer of deeper dives for premium members. We publish full dossiers on single peptides like

GLP/peptide talk translation: • “Gray market = sold outside authorized prescription/pharmacy channels. • “Research” = labeled “for research—not approved for human use” to enable sale in the US. • GLP-1 = the hormone pathway targeted by this drug class (Sema) • GLP-2 = https://t.co/jw0vVEq3xI

Standing offer to every peptide price tracker: list us. If any vendor on your board beats our price on the same product, we'll match it and publish the comparison. Current pricing (sold as 10-vial kits): Retatrutide 10mg — $1.12/mg Tirzepatide 10mg — $0.69/mg Semaglutide 10mg

RT @MounjaroNotes: Tirzepatide is GLP-1 + GIP, but semaglutide is more GLP-1-heavy. Since GLP-1 plays a major role in satiety and hunger s…